- Advertisement -

Related

Rhenman & Partners Boosts Biopharma Expertise

- Advertisement -

Stockholm (HedgeNordic) – Rhenman & Partners is expanding its five-person investment team with the hiring of Amennai Beyeen as a biopharma analyst. He joins from global healthcare company Novartis.

“We are very happy to welcome Amennai to Rhenman & Partners,” says Henrik Rhenman, co-founder and CIO at Rhenman & Partners. “Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team.”

“We are very happy to welcome Amennai to Rhenman & Partners.”

Amennai Beyeen has worked for about 12 years at Novartis, focusing on the development and launch of new drugs. He also holds a doctorate in neuroimmunology from Karolinska Institutet in Stockholm. Beyeen will join the five-person investment team running the healthcare-focused equity hedge fund Rhenman Healthcare Equity L/S. He will have a particular focus on biopharma companies and the development of new drugs and treatments.

“It is very exciting to start at Rhenman & Partners,” Amennai Beyeen comments on joining the Swedish healthcare-focused asset manager. “I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years,” he continues. “I look forward to joining this competent team and contributing with my experience from the life science sector.”

Rhenman & Partners Asset Management has been running its long-biased equity hedge fund with an exclusive focus on healthcare since mid-2009, delivering an annualized return of 17.3 percent through November 2022. The fund’s main share class (IC1 EUR) edged down 1.6 percent in the first 11 months of this year. Rhenman Healthcare Equity L/S oversees €923 million in assets under management.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Afa Försäkring Puts Operational Value Creation at the Centre of Private Equity

The challenging private equity environment, marked by higher financing costs, slower distributions and difficult exit conditions, is putting greater pressure on managers to demonstrate...

Thorbjörn Wallentin Parts Ways with OQAM as Credit Takes Centre Stage

After more than a decade helping build Malmö-based asset management firm OQAM, co-founder and Chief Investment Officer Thorbjörn Wallentin is stepping away from his...

The Investment Case for European Infrastructure Debt

Europe’s infrastructure needs are expanding as governments and businesses seek greater energy security, lower emissions and more resilient digital and electricity networks. For debt...

Bliwa Balances Fixed Income Stability with Selective Risk-Taking

For insurers, fixed income must do more than generate returns. It needs to provide stability, preserve liquidity, and help match investments to liabilities. At...

Beyond the Yield Premium: Finding Value in Nordic High Yield

The Nordic high-yield market combines shorter maturities, a high share of floating-rate bonds, stronger creditor protections in many transactions and a persistent yield premium...

An Invitation-Only Market: Evli’s Approach to Nordic Mid-Market Loans

The Nordic credit markets offer investors a distinctive combination of attractive yields, floating-rate instruments and access to high-quality mid-market companies. The region’s established private...

Allocator Interviews

Voices

Request for Proposal

- Advertisement -